The Importance of DSCSA to Dispensers

The Drug Supply Chain Security Act (DSCSA) is a United States federal law that was enacted in 2013 in order to prevent counterfeit and stolen drugs from entering the legitimate pharmaceutical supply chain.

The DSCSA has a number of provisions that aim to improve the security of the drug supply chain in the United States. One of the key provisions is to create an interoperable system for tracking and tracing prescription drugs. This system will allow the FDA to identify and track drugs as they move through the pharmaceutical supply chain from the manufacturer to the dispensers and ultimately to the customer.

This white paper was written by Excellis Health Solutions’ Stephen Kovary, RPh (Executive Vice President) and Caitrin O’Shea (Senior Strategy Consultant).

Read the White Paper

In collaboration with our parent company NNIT and their group companies SL Controls and Excellis Health Solutions comes the very first white paper. It gives a very holistic view of the digitalization of the complete production process and supply chain integration.

What is this white paper about?
In the future pharma production, it will be essential to manage increasingly complex production processes and manufacturing micro-batches tailored to more specific therapies and patient groups.

The enabler is a connected factory, where data and information can flow freely both within the production site and externally. This requires a fully digitized and integrated process and control equipment across all areas of operation including supply chain integration.

This whitepaper shows you

• Challenges and the potential benefits of an integrated factory
• Best practices and solutions for making it happen
• Common mistakes and pitfalls

Excellis’ Managing Consultant in SME, Sean O’Hearen, has written two chapters in Professor Jeremy Wilson’s book, Brand Protection and the Global Risk of Product Counterfeits: A Total Business Solution Approach!

According to Professor Wilson, the book is “Based on substantial field research and practice, this book provides a framework for building and advancing brand protection programs that are strategic, comprehensive, and evidence based.”

The book will be released globally on July 19, 2022.

For more information, click here.

Excellis Health Solutions and parent company NNIT will be participating in the DIA Global Annual Meeting 2022 in Chicago, IL.

Brook Casselberry, AVP, US Life Sciences Advisory and Consulting is chairing the session “Data Integrity Across the Production Lifecycle” and Excellis’ Chrisoph Krahenbuhl, Senior Director will be a speaker in this session.

The presenters in this session will discuss data integrity in product design, clinical development, and supply chain.

Learn More